Buda Juice Targets NYSE Listing with 'UltraFresh' IPO

Ticker: BUDA · Form: S-1/A · Filed: Dec 1, 2025 · CIK: 2079720

Sentiment: mixed

Topics: IPO, Beverages, Health & Wellness, Emerging Growth Company, NYSE Listing, Cold-Pressed Juice, Food & Beverage

Related Tickers: BUDA

TL;DR

**BUDA's IPO is a high-risk, high-reward bet on disrupting the stale juice market with 'UltraFresh' innovation, but watch for NYSE listing approval and execution against established giants.**

AI Summary

Buda Juice, LLC, soon to be Buda Juice, Inc. (BUDA), is launching an IPO of 2,666,667 shares of common stock at an estimated price range of $7.50 to $9.00 per share. The company is pioneering the 'UltraFresh™' juice category, focusing on cold-crafted, never heat-treated or HPP-processed citrus-based drinks. This strategic pivot from retail stores to selling to established retailers aims for broader market impact and scalable growth. The offering is contingent upon successful listing on the NYSE under the symbol 'BUDA'. As an emerging growth company, BUDA will comply with reduced public company reporting requirements. The company has granted a 45-day over-allotment option to underwriters for up to an additional 400,000 shares, and warrants to purchase up to 266,666 shares (or 306,667 with over-allotment) at an exercise price of $9.375.

Why It Matters

Buda Juice's IPO could redefine the refrigerated juice market by introducing its 'UltraFresh' category, potentially challenging established players relying on HPP or pasteurization. For investors, this offers exposure to a high-growth segment within the health and wellness beverage industry, but with the inherent risks of an emerging growth company and a new market listing. Employees and customers could benefit from a company focused on product integrity and expanding access to genuinely fresh options. The competitive landscape, dominated by larger, more processed juice brands, could see disruption if Buda Juice's model gains significant traction, pushing others to innovate or lose market share.

Risk Assessment

Risk Level: high — The offering involves a 'high degree of risk' as explicitly stated on page 10 of the prospectus. The company is an 'emerging growth company' and the IPO is contingent upon successful NYSE listing, which is not assured. There is no prior public market for its common stock, making valuation and future performance highly speculative.

Analyst Insight

Investors should carefully evaluate the 'Risk Factors' section starting on page 10 and consider the speculative nature of an emerging growth company with no prior public market. Wait for confirmation of the NYSE listing and assess initial market reception before making an investment decision, as the offering is contingent on this approval.

Financial Highlights

revenue
$11.2 million
gross Margin
N/A
total Assets
N/A
cash Position
$0.00
revenue Growth
+41.8%
total Debt
N/A

Revenue Breakdown

SegmentRevenueGrowth
Buda Juice (Organic)$11.2 million+41.8%
Buda Fresh (Value-Forward)$11.2 million+41.8%
Private Label Products$11.2 million+41.8%

Key Numbers

Key Players & Entities

FAQ

What is Buda Juice's primary business model and product offering?

Buda Juice is pioneering the 'UltraFresh™' juice category, offering cold-crafted citrus-based drinks that are never heat-treated or HPP-processed. They have strategically shifted from operating their own retail stores to selling to established retailers to achieve broader market impact.

What is the estimated price range for Buda Juice's IPO shares?

The estimated initial public offering price for Buda Juice's common stock is between $7.50 and $9.00 per share. The company has assumed an IPO price of $7.50 for certain financial data in the prospectus.

What is the significance of Buda Juice being an 'emerging growth company'?

As an 'emerging growth company,' Buda Juice has elected to comply with certain reduced public company reporting requirements for this prospectus and future filings, which can impact the level of disclosure and regulatory scrutiny.

What are the key risks associated with investing in Buda Juice's IPO?

Investing in Buda Juice's Common Stock involves a high degree of risk, including the fact that there has been no prior public market for its shares, and the offering is contingent upon successful listing on the NYSE, which is not guaranteed.

Who is the CEO of Buda Juice and what is their vision for the company?

Horatio Lonsdale-Hands is the Co-Founder and Chief Executive Officer of Buda Juice. His vision is to make UltraFresh™ juice the new standard, providing clean beverages in every grocery store across the U.S. without compromise on safety, taste, or nutrients.

How many shares is Buda Juice offering in its initial public offering?

Buda Juice, Inc. is registering 2,666,667 shares of common stock for its initial public offering. Additionally, the underwriter has a 45-day option to purchase up to an additional 400,000 shares.

What is the planned stock exchange listing for Buda Juice?

Buda Juice has applied to list its Common Stock on the New York Stock Exchange (NYSE) under the symbol 'BUDA'. The closing of this Offering is contingent upon the successful listing of its Common Stock on NYSE.

What is the 'Conversion' mentioned in the Buda Juice S-1/A filing?

The 'Conversion' refers to Buda Juice, LLC's plan to undertake a statutory conversion into a Delaware corporation named Buda Juice, Inc. before the effectiveness of this registration statement, in connection with the Offering.

How does Buda Juice differentiate its products from competitors?

Buda Juice differentiates itself by pioneering 'UltraFresh™' juice, which means their cold-crafted citrus-based drinks are never heat-treated, never HPP-processed, and always cold, aiming to preserve essential nutrients and genuine taste often lost in conventional processing.

What is the underwriter's over-allotment option for Buda Juice's IPO?

The Company has granted a 45-day option to the underwriter to purchase up to an additional 400,000 shares of Common Stock solely to cover over-allotments, if any, in connection with the Offering.

Risk Factors

Industry Context

Buda Juice operates in the fresh juice market, a segment characterized by growing consumer demand for healthier and natural beverage options. The company differentiates itself by pioneering the 'UltraFresh™' category, focusing on a cold chain process that preserves freshness without heat or HPP treatment. This positions them to compete against both traditional shelf-stable juices and in-store juicing operations by offering a scalable, high-quality solution to retailers.

Regulatory Implications

As an emerging growth company, Buda Juice will benefit from reduced public company reporting requirements under the JOBS Act. However, the company must secure approval from the NYSE for its listing application to proceed with the IPO. Compliance with food safety regulations and maintaining the integrity of their cold chain process are ongoing regulatory considerations.

What Investors Should Do

  1. Evaluate the competitive landscape and Buda Juice's market penetration strategy.
  2. Assess the execution risk associated with the planned geographic expansion.
  3. Monitor the company's ability to maintain cold chain integrity throughout its supply chain.
  4. Understand the dilution impact of underwriter warrants.

Key Dates

Glossary

UltraFresh™
Buda Juice's proprietary category for cold-crafted, never heat-treated or HPP-processed citrus-based drinks. (Defines the company's unique selling proposition and product differentiation.)
Cold Chain
A temperature-controlled supply chain that maintains a specific low temperature (35°F in Buda Juice's case) from production to the point of sale. (Crucial for Buda Juice's product quality, shelf life, and safety claims.)
HPP-Processed
High-Pressure Processing, a method of food preservation that uses high pressure to kill microorganisms without heat. (Buda Juice differentiates itself by *not* using HPP, emphasizing its 'never heat-treated' approach.)
CAGR
Compound Annual Growth Rate, a measure of average annual growth over a specified period. (Used to quantify the company's revenue growth rate of 41.8% from 2022 to 2024.)
Emerging Growth Company
A company that has total annual gross revenue of less than $1.235 billion during its most recently completed fiscal year. (Allows Buda Juice to comply with reduced public company reporting requirements.)
Over-allotment Option
An option granted to underwriters to purchase additional shares from the issuer at the IPO price, typically to cover excess demand. (Allows underwriters to sell up to 400,000 additional shares, potentially increasing the offering size.)
Underwriter Warrants
Warrants issued to underwriters as part of the IPO compensation, giving them the right to buy shares at a specified price. (Represents a form of compensation for the underwriters and a potential future dilution for shareholders.)

Year-Over-Year Comparison

This S-1/A filing indicates significant revenue growth, with revenue increasing from $5.6 million in 2022 to $11.2 million in 2024, representing a 41.8% CAGR. While specific details on net income, EPS, and debt-to-equity ratios are not provided in this excerpt, the focus on expansion and the 'UltraFresh™' category suggests a strategic shift and investment phase. New risks related to the IPO process, such as NYSE listing approval, and the operational complexities of scaling the cold chain infrastructure are highlighted.

Filing Stats: 4,305 words · 17 min read · ~14 pages · Grade level 14.7 · Accepted 2025-12-01 17:00:29

Key Financial Figures

Filing Documents

USE OF PROCEEDS

USE OF PROCEEDS 32 DIVIDEND POLICY 33 CAPITALIZATION 34

DILUTION

DILUTION 35 MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS 36

BUSINESS

BUSINESS 46 MANAGEMENT 55 EXECUTIVE AND DIRECTOR COMPENSATION 62 CERTAIN RELATIONSHIPS AND RELATED PARTY TRANSACTIONS 63 PRINCIPAL STOCKHOLDERS 64

DESCRIPTION OF CAPITAL STOCK

DESCRIPTION OF CAPITAL STOCK 65 SHARES ELIGIBLE FOR FUTURE SALE 67 MATERIAL U.S. FEDERAL INCOME TAX CONSEQUENCES TO NON-U.S. HOLDERS OF OUR COMMON STOCK 68

UNDERWRITING

UNDERWRITING 72 LEGAL MATTERS 75 EXPERTS 75 WHERE YOU CAN FIND MORE INFORMATION 75 INDEX TO FINANCIAL STATEMENTS F-1 i Neither we nor the underwriter have authorized anyone to provide any information or to make any representations other than those contained in this prospectus or in any free writing prospectus prepared by or on behalf of us or to which we have referred you. We take no responsibility for and can provide no assurance as to the reliability of any other information that others may give you. This prospectus is an offer to sell only the shares of Common Stock offered hereby, but only under circumstances and in jurisdictions where it is lawful to do so. The information contained in this prospectus or in any applicable free writing prospectus is current only as of its date, regardless of its time of delivery or any sale of our Common Stock. Our business, financial condition, results of operations and prospects may have changed since that date. For investors outside the United States: Neither we nor the underwriter have done anything that would permit this Offering or possession or distribution of this prospectus in any jurisdiction where action for that purpose is required, other than in the United States. Persons outside the United States who come into possession of this prospectus must inform themselves about, and observe any restrictions relating to, the Offering of the shares of Common Stock and the distribution of this prospectus outside the United States. This prospectus contains forward-looking statements that are subject to a number of risks and uncertainties, many of which are beyond our control. See “Risk Factors” and “Special Note Regarding Forward-Looking Statements.” ii ABOUT THIS PROSPECTUS Except where the context otherwise requires or where otherwise indicated throughout this registration statement, the terms “Buda Juice, LLC,” “Buda Juice, Inc.,” “Buda Juice,&rd

financial statements and the related notes included elsewhere in this prospectus, before making an investment decision

financial statements and the related notes included elsewhere in this prospectus, before making an investment decision. If our listing application is not approved by the New York Stock Exchange (“NYSE”), we will not be able to consummate the Offering. Overview Buda Juice is pioneering the UltraFresh TM juice category through our end-to-end cold chain platform that delivers always cold, freshly crafted juice, lemonades and wellness shots to grocery retailers in Texas. We bridge the gap between shelf-stable products and operationally challenging in-store juicing, enabling any retailer to offer truly fresh and safe juice without infrastructure investment or operational complexity. Our breakthrough lies in solving the industry’s fundamental challenge: delivering UltraFresh TM quality on a retail scale. We maintain continuous 35°F temperature control from fruit to shelf, delivering products with 8-12 day shelf life - long enough for retail distribution yet fresh enough to preserve authentic taste. This eliminates the traditional tradeoffs between shelf life, flavor, and nutrient quality in the industry. We have validated our model through strong financial performance, growing revenue from $5.6 million in 2022 to $11.2 million in 2024, representing a 41.8% CAGR. Currently operating from our Dallas plant, we are executing a disciplined geographic expansion strategy with planned facilities in South Carolina (2026) and Arizona/Nevada (2027), enabling us to serve a large percentage of the U.S. population. Our Products Our product portfolio consists of fresh citrus juice, fresh citrus-based line of lemonades and wellness shot offerings across multiple brand lines and retail customers, all produced using our cold chain process: Products (1) Buda Juice (Organic) Wellness shots in 2 oz format Available in 2-pack and 6-pack glass bottle configurations (2) Buda Fresh – Value-Forward Offering (Non-Organic) 12 oz Lime Juice, 16 oz

View Full Filing

View this S-1/A filing on SEC EDGAR

View on Read The Filing